Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Ponatinib as a consolidation strategy for a second attempt at TKI discontinuation in chronic myeloid leukemia: Interim results from the restop Trial

Almudena Zaratiegui Vergara, Gonzalo Carreño, Francisca Ferrer Marin, Blanca Xicoy, María Teresa Gómez Casares, Fermin Sanchez-Guijo, M Concepción Ruiz Nuño, Santiago Osorio Prendes, Raquel De Paz, Ana Isabel Rosell Mas, Elvira Mora Casterá, María Alicia Senin, Juan Carlos Hernandez Boluda, Rosa Ayala Diaz, Valentín García Gutiérrez, Joaquin Martinez Lopez

Blood (2025) 146 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2025-3778

Published: 2025

Journal Articles

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Blood (2025) 146 (Supplement 1): 2562.

https://doi.org/10.1182/blood-2025-2562

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

Acquired regions of homozygosity in adult B-cell acute lymphoblastic leukemia: Insights from a machine learning–powered analysis of genomic data from a multicenter cohort

Gianfranco Lapietra, Juan Manuel Rosa-Rosa, Mireia Morgades, Neus Ruiz-Xivillé, Anna Torrent, Mar Mallo, Alberto Hernández-Sánchez, Josgrey Del Valle Navas Acosta, Isabel Granada, Sabina Chiaretti, Ricardo Sanchez, Esperanza Such, Jesus Maria Hernandez Rivas, Alberto Orfao, Rosa Ayala Diaz, Joaquin Martinez-Lopez, Jose Tomas Navarro, Josep-Maria Ribera, Jordi Ribera

Blood (2025) 146 (Supplement 1): 6879.

https://doi.org/10.1182/blood-2025-6879

Published: 2025

Journal Articles

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Blood (2025) 146 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2025-1719

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

Impact of molecular profile and variant allele frequency in patients with Acute Myeloid Leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group

Rafael Colmenares, Eva Barragán, Rebeca Rodriguez-Veiga, Laura Torres-Miñana, Joaquín Sánchez-García, Mar Tormo, Teresa Bernal Del Castillo, Pilar Martinez Sanchez, Eduardo Rodríguez-Arbolí, Cristina Gil, Elena Soria-Saldise, Josefina Serrano, Mercedes Colorado, María García-Fortes, Cristina Bilbao, José Luis López Lorenzo, Maria Jose Larrayoz, Esther Pérez-Santaolalla, Esperanza Lavilla-Rubira, Lorenzo Algarra, Maria Carmen García-Garay, Carmen Chillon, Melissa Torres-Ochando, Raimundo García-Boyero, Carmen Couto, Ágata Almela, Victor Noriega Concepción, Marta Callejas, Manuel Barrios García, Soledad Casado, Amaia Balerdi Malcorra, Ana Cabello, Jorge Labrador, María Carmen Mateos, María Luz Amigo, Manuel Pérez-Encinas, Maria Jose Garcia, Lisette Costilla-Barriga, Juan Miguel Bergua Burgues, Gonzalo Carreño, Joaquin Martinez-Lopez, Rosa Ayala Diaz, Pau Montesinos

Blood (2025) 146 (Supplement 1): 6998.

https://doi.org/10.1182/blood-2025-6998

Published: 2025

Journal Articles

Uncovering molecular trajectories in follicular lymphoma using hidden markov models of ctdna dynamics

Blood (2025) 146 (Supplement 1): 5322.

https://doi.org/10.1182/blood-2025-5322

Published: 2025

Journal Articles

AI-based classification and outcome prediction in BCR::ABL1-like B-cell precursor acute lymphoblastic leukemia patients using targeted RNA-seq

Juan Manuel Rosa-Rosa, Jordi Ribera, Mireia Morgades, Isabel Granada, Rosa Ayala Diaz, Susana Barrera, Alberto Hernández-Sánchez, Josgrey Del Valle Navas Acosta, María Herrero García, Esperanza Such, Anna Torrent, Rosa Coll, Marta Cervera, Clara Maluquer Artigal, Jesus Maria Hernandez Rivas, Alberto Orfao, Josep-Maria Ribera, Joaquin Martinez-Lopez, Ricardo Sanchez

Blood (2025) 146 (Supplement 1): 4358.

https://doi.org/10.1182/blood-2025-4358

Published: 2025

Journal Articles

Validation of the high-risk consensus genomic staging system in the era of bispecific antibodies: Role of NGS and cytogenetic reclassification

Maria Sanchez-Tabernero, Magdalena Corona, Cristian Gutiérrez Padilla, Jose Sanchez-Pina, Rafael Alonso, Inmaculada Rapado, Nieves Lopez-Muñoz, Gonzalo Carreño, Susana Cortijo, Maria Teresa Cedena Romero, Manuela Fernández, Rosa Ayala Diaz, Maria Calbacho, Joaquin Martinez-Lopez

Blood (2025) 146 (Supplement 1): 5781.

https://doi.org/10.1182/blood-2025-5781

Published: 2025

Journal Articles

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

Blood (2025) 146 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2025-1993

Published: 2025

Journal Articles

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Blood (2025) 146 (Supplement 1): 5574.

https://doi.org/10.1182/blood-2025-5574

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Ponatinib as a consolidation strategy for a second attempt at TKI discontinuation in chronic myeloid leukemia: Interim results from the restop Trial

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Acquired regions of homozygosity in adult B-cell acute lymphoblastic leukemia: Insights from a machine learning–powered analysis of genomic data from a multicenter cohort

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Impact of molecular profile and variant allele frequency in patients with Acute Myeloid Leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group

Uncovering molecular trajectories in follicular lymphoma using hidden markov models of ctdna dynamics

AI-based classification and outcome prediction in BCR::ABL1-like B-cell precursor acute lymphoblastic leukemia patients using targeted RNA-seq

Validation of the high-risk consensus genomic staging system in the era of bispecific antibodies: Role of NGS and cytogenetic reclassification

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only